Presentation Authors: Se Young Choi, Bumjin Lim, Jae Hyeon Han, Yoon Soo Kyung, Dong Hyeon An, Hwiwoo Kim, Wonchul Lee*, Han Kyu Chae, Jaehoon Lee, Wonseok Choi, Dalsan You, In Gab Jeong, Choung-Soo Kim, Seoul, Korea, Republic of
Introduction: We evaluated the efficacy of self-expandable covered metallic stent in prostatic urethra comparing benign prostatic disease and prostate cancer (PC).
Methods: We reviewed 42 cases of self-expandable covered metallic stents with barbs. The cohort was divided into two groups of non-PC and PC. Variables of uroflowmetry, residual urine volume, and International Prostate Symptoms Score (IPSS) with quality of life (QOL) and duration from the insertion to removal were surveyed. Logistic regression analysis was used to predict the early stent removal within 3 months.
Results: PC group showed similar baseline characteristics such as age, body mass index, and prostate volume to non-PC group. Average flow rate (4.9ml/sec vs 2.0ml/sec, p=0.044), peak flow rate (6.3ml/sec vs 11.8ml/sec, p=0.010), flow time (25.9sec vs 49.3sec, p=0.018), residual urine (34ml vs 124ml, p=0.019), IPSS (10 vs 26, p < 0.001), and QOL (2 vs 5, p < 0.001) were improved after the stent insertion comparing before the insertion, respectively. There was no difference in median time to stent removal between non-PC and PC (6.0 months vs 5.7 months, p=0.627). In analysis for predicting early stent removal within 3 months, there was no significant factor in past medical history, prostate volume, PC, or stent size.
Conclusions: This stent was maintained during about 6 months with improved objective and subjective outcomes. PC group showed comparable maintenance period to non-PC group. Short life expectancy, unable general anesthesia, prior radiation therapy and failure to previous operation against prostatic obstruction can be the proper candidates for the stent insertion.